Hashimoto N, Majima T, Ichimura K, Iwata T, Suguro H, Horie T
First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Nihon Kyobu Shikkan Gakkai Zasshi. 1997 Jun;35(6):634-40.
Eicosapentaenoic acid (EPA) is composed of 20 unsaturated fatty acids and is similar to arachidonic acid. Epadel, the drug made from EPA, is reported not only to reduce levels of serum lipids, but also to have antiinflammatory and antiallergic effects. EPA may exert these effects via control of the production of prostanoids and leukotrienes. We studied the effects of EPA in patients with bronchial asthma who had hyperlipidemia. The patents were given EPA at 1800 mg/day and they recorded signs and symptoms in an asthma diary during a 2-week observation period and the 8 weeks during which they took the drug. Peak flow, leukotriene B4 concentration in urine, Leukotriene E4 concentration in urine, IgE level, total cholesterol level, and triglyceride level were measured before and after the 8 weeks of medication. Administration of EPA was associated with improvements in symptom score, therapeutic score, asthma score, and peak flow. EPA may be useful in patients with asthma complicated by hyperlipidemia.
二十碳五烯酸（EPA）由20种不饱和脂肪酸组成，与花生四烯酸相似。据报道，由EPA制成的药物Epadel不仅能降低血脂水平，还具有抗炎和抗过敏作用。EPA可能通过控制前列腺素和白三烯的产生来发挥这些作用。我们研究了EPA对患有高脂血症的支气管哮喘患者的影响。患者每天服用1800毫克EPA，并在为期2周的观察期以及服药的8周内，在哮喘日记中记录体征和症状。在服药8周前后测量了呼气峰值流速、尿中白三烯B4浓度、尿中白三烯E4浓度、IgE水平、总胆固醇水平和甘油三酯水平。服用EPA与症状评分、治疗评分、哮喘评分和呼气峰值流速的改善有关。EPA可能对合并高脂血症的哮喘患者有用。
